Fig. 2: Kaplan–Meier plots of the long-term efficacy endpoints EFS and DFS. | Nature Communications

Fig. 2: Kaplan–Meier plots of the long-term efficacy endpoints EFS and DFS.

From: Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial

Fig. 2

a EFS in the ITT population and b DFS in all patients who underwent surgery. 95% CIs and p values (two-sided) for differences in event rates were from z-tests using the standard errors for the Kaplan–Meier estimates. CI confidence interval, DFS disease-free survival, EFS event-free survival, HR hazard ratio, ITT intention-to-treat.

Back to article page